L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3864-3869

  Cruciani, Ricardo A ^a,b   Zhang, Jenny J ^g   Manola, Judith ^c   Cella, David ^d   Ansari, Bilal ^e   Fisch, Michael J ^f  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e is an assistant professor of nursing at Bethel College   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; PLACEBO;

ADULT; ARTICLE; BRIEF FATIGUE INVENTORY; CANCER INVASION; CANCER PATIENT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE INSTRUMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARNITINE; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84869114410     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.2180     Document Type: Article

References (16)

1. Barnes P, Bloom B, Nahin R: Complementary and alternative medicine use among adults and children: United States. Nat Health Stat Rep 10:1-23, 2008
2. Pekala J, Patkowska-Sokoła B, Bodkowski R: L-carnitine: Metabolic functions and meaning in human life. Curr Drug Metab 12:667-678, 2011
3. Dodson WL, Sachan DS, Krauss S, et al: Alterations of serum and urinary carnitine profiles in cancer patients: Hypothesis of possible significance. J Am Coll Nutr 8:133-142, 1989 (Pubitemid 20047675)
4. Laviano A, Molfino A, Seelaender M, et al: Carnitine administration reduces cytokine levels, improves food intake, and ameliorates body composition in tumor-bearing rats. Cancer Invest 29:696-700, 2011
5. Esteban-Cruciani NV: Severe carnitine deficiency in children with AIDS: Improved functional activity status after supplementation. Pediatr Res 49:254, 2001 (abstr)
6. Graziano F, Bisonni R, Catalano V, et al: Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer 86:1854-1857, 2002
7. Cruciani RA, Dvorkin E, Homel P, et al: L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: A preliminary analysis. Ann N Y Acad Sci 1033:168-176, 2004 (Pubitemid 39656749)
8. Cruciani RA, Dvorkin E, Homel P, et al: L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: A doubleblind, placebo-controlled study. J Pain Symptom Manage 37:622-631, 2009
9. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999 (Pubitemid 29115600)
10. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
11. Radloff LS: CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Measur 1:385-401, 1977
12. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997 (Pubitemid 27147321)
13. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
14. Lan HHG, DeMets DL: Discrete boundaries for clinical trials. Biometrika 70:659-663, 1983
15. Mantovani G, Macciò A, Madeddu C, et al: Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15:200-211, 2010
16. Macciò A, Madeddu C, Gramignano G, et al: A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124:417-425, 2012